top of page

STIFEL 2026: Korsana Biosciences is using a proprietary brain shuttle and a beta amyloid targeting therapy and aims to take Alzheimer's treatment to the next level

2 hours ago

1 min read

President and CEO Jonathan Violin compares and contrasts his product with other brain shuttles and discusses the road ahead. They will present preclinical data at CTAD next week and the clinical program will ramp up and have initial data in 2027. Korsana recently went public through a reverse merger.

https://vimeo.com/1245530572?share=copy&fl=sv&fe=ci

Coverage brought to you by

Recent Posts

See All

STIFEL 2026: Alkermes' new CEO Blair Jackson describes his priorities for the company - which include a heavy focus on the emerging orexin agonist class

BIO-Europe 2026: Envisagenics is harnessing RNA splicing as its therapeutic approach - which may open up biology to novel targets

BIO-Europe 2026: Atrogi aims to harness beta-2 agonism to increase muscle mass for a whole host of conditions, including muscle loss due to GLP medicines

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

Learn more